Pneumocystis carinii.Dihydropteroate Synthase Mutations and Treatment with Sulfa or Sulfone Regimens: a Proposal for Standardized Definitions for Clinical Evaluation
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The existence of TMP-SMX-resistant Pneumocystis in these regions, combined with the general absence of invasive diagnostic procedures and intensive care facilities, stresses the importance of further study.
“The existence of TMP-SMX–resistant Pneumocystis in these regions, combined with the general absence of invasive diagnostic procedures (e.g., bronchoscopy that might establish an earlier diagnosis of PCP when the outcome is better) and intensive care facilities (e.g., mechanical ventilation that might support patients until PCP treatment can be effective), stresses the importance of further study (”
From Dihydropteroate Synthase Gene Mutations in<i>Pneumocystis</i>and Sulfa Resistance (2004) · cites this paper as [40]
PCP is increasingly being recognized as an important cause of illness in sub-Saharan Africa, Southeast Asia, and Latin America.
“Second, PCP is increasingly being recognized as an important cause of illness in these regions.”
From Dihydropteroate Synthase Gene Mutations in<i>Pneumocystis</i>and Sulfa Resistance (2004) · cites this paper as [40]
The treatment options for PCP in these regions are often limited to TMP-SMX, since regimens such as pentamidine, clindamycin plus primaquine, trimetrexate, and atovaquone are unavailable.
“Next, the treatment options for PCP in these regions are often limited to TMP-SMX, since regimens such as pentamidine, clindamycin plus primaquine, trimetrexate, and atovaquone are unavailable.”
From Dihydropteroate Synthase Gene Mutations in<i>Pneumocystis</i>and Sulfa Resistance (2004) · cites this paper as [40]
TMP-SMX-resistant Pneumocystis exists in these regions.
“The existence of TMP-SMX–resistant Pneumocystis in these regions, combined with the general absence of invasive diagnostic procedures (e.g., bronchoscopy that might establish an earlier diagnosis of PCP when the outcome is better) and intensive care facilities (e.g., mechanical ventilation that might support patients until PCP treatment can be effective), stresses the importance of further study (”
From Dihydropteroate Synthase Gene Mutations in<i>Pneumocystis</i>and Sulfa Resistance (2004) · cites this paper as [40]
In many of these regions, programs to use TMP-SMX as multiopportunistic infection prophylaxis are being implemented.
“In many of these regions, programs to use TMP-SMX as multiopportunistic infection prophylaxis are being implemented, and Pneumocystis that contains DHPS mutations can be expected.”
From Dihydropteroate Synthase Gene Mutations in<i>Pneumocystis</i>and Sulfa Resistance (2004) · cites this paper as [40]
There is a general absence of invasive diagnostic procedures and intensive care facilities in these regions.
“The existence of TMP-SMX–resistant Pneumocystis in these regions, combined with the general absence of invasive diagnostic procedures (e.g., bronchoscopy that might establish an earlier diagnosis of PCP when the outcome is better) and intensive care facilities (e.g., mechanical ventilation that might support patients until PCP treatment can be effective), stresses the importance of further study (”
From Dihydropteroate Synthase Gene Mutations in<i>Pneumocystis</i>and Sulfa Resistance (2004) · cites this paper as [40]
Pneumocystis that contains DHPS mutations can be expected in many of these regions.
“In many of these regions, programs to use TMP-SMX as multiopportunistic infection prophylaxis are being implemented, and Pneumocystis that contains DHPS mutations can be expected.”
From Dihydropteroate Synthase Gene Mutations in<i>Pneumocystis</i>and Sulfa Resistance (2004) · cites this paper as [40]
Most HIV-infected persons worldwide reside in sub-Saharan Africa, Southeast Asia, and Latin America, places where access to antiretroviral therapy and PCP prophylaxis are limited.
“First, most HIV-infected persons worldwide reside in sub-Saharan Africa, Southeast Asia, and Latin America, places where access to antiretroviral therapy and PCP prophylaxis are limited.”
From Dihydropteroate Synthase Gene Mutations in<i>Pneumocystis</i>and Sulfa Resistance (2004) · cites this paper as [40]
Cites
Triglia, T., Menting, J. G. T., Wilson, C. M., & Cowman, A. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13944 · Cited by 421 · see citing works
Brooks, D. R., Wang, P., Read, M., Watkins, W. M., Sims, P. F. G., & Hyde, J. E. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00397.x · Cited by 369 · see citing works
Helweg-Larsen, J., Benfield, T. L., Eugen-Olsen, J., Lundgren, J. D., & Lundgren, B. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03320-6 · Cited by 274 · see citing works
Triglia, T., Wang, P., Sims, P. F. G., Hyde, J. E., & Cowman, A. F. (1998) · The EMBO Journal · doi:10.1093/emboj/17.14.3807 · Cited by 270 · see citing works
Beard, C. B., Carter, J. L., Keely, S. P., Huang, L., Pieniazek, N. J., Moura, I. N. S., Roberts, J. M., Hightower, A. W., Bens, M. S., Freeman, A. R., et al. (2000) · Emerging infectious diseases · doi:10.3201/eid0603.000306 · Cited by 241 · see citing works
Self-citationKazanjian, P., Locke, A. B., Hossler, P. A., Lane, B. R., Bartlett, M. S., Smith, J. W., Cannon, M., & Meshnick, S. R. (1998) · AIDS · doi:10.1097/00002030-199808000-00009 · Cited by 171 · see citing works
Ma, L., Borio, L., Masur, H., & Kovacs, J. A. (1999) · The Journal of Infectious Diseases · doi:10.1086/315148 · Cited by 169 · see citing works
Kazanjian, P., Armstrong, W., Hossler, P. A., Burman, W., Richardson, J., Lee, C., Crane, L., Katz, J., & Meshnick, S. R. (2000) · The Journal of Infectious Diseases · doi:10.1086/315719 · Cited by 164 · see citing works
Huang, L., Beard, C. B., Creasman, J., Levy, D., Duchin, J. S., Lee, S., Pieniazek, N., Carter, J. L., del Rio, C., Rimland, D., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315824 · Cited by 149 · see citing works
Self-citationLópez, P., Espinosa, M., Greenberg, B., & Lacks, S. A. (1987) · Journal of Bacteriology · doi:10.1128/jb.169.9.4320-4326.1987 · Cited by 132 · see citing works
Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era.
Martin, J. N., Rose, D. A., Hadley, W. K., Perdreau‐Remington, F., Lam, P. K., & Gerberding, J. L. (1999) · The Journal of Infectious Diseases · doi:10.1086/315132 · Cited by 126 · see citing works
Navin, T. R., Beard, C. B., Huang, L., del Rio, C., Lee, S., Pieniazek, N. J., Carter, J. L., Le, T., Hightower, A., & Rimland, D. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05705-1 · Cited by 117 · see citing works
Self-citationJajosky, R. A., Harrison, R., Reinisch, F., Flattery, J., Chan, J., Tumpowsky, C., Davis, L., Reilly, M. J., Rosenman, K. D., Kalinowski, D. J., et al. (1999) · PubMed · Cited by 105 · see citing works
Fermér, C., Kristiansen, B., Sköld, O., & Swedberg, G. (1995) · Journal of Bacteriology · doi:10.1128/jb.177.16.4669-4675.1995 · Cited by 94 · see citing works
Characterization of Mutations Contributing to Sulfathiazole Resistance in Escherichia coli
Vedantam, G., Guay, G. G., Austria, N. E., Doktor, S. Z., & Nichols, B. P. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.1.88 · Cited by 82 · see citing works
(1999) · PsycEXTRA Dataset · doi:10.1037/e547882006-001 · Cited by 77 · see citing works
Swedberg, G., Ringertz, S. H., & Sköld, O. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1062 · Cited by 73 · see citing works
Point Mutations in the Dihydropteroate Synthase Gene Causing Sulfonamide Resistance
Swedberg, G., Fermér, C., & Sköld, O. (1993) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2960-6_113 · Cited by 42 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dihydropteroate Synthase Gene Mutations in<i>Pneumocystis</i>and Sulfa Resistance
Huang, L., Crothers, K., Atzori, C., Benfield, T., Miller, R., Rabodonirina, M., & Helweg-Larsen, J. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1010.030994 · Cited by 131 · see citing works
Self-citationCROTHERS, K., HUANG, L., MORRIS, A., FOX, M., GRONER, G., TURNER, J. R., MERRIFIELD, C., EISER, S., FRIEDLY, J., GRAVARI, E., et al. (2003) · Journal of Eukaryotic Microbiology · doi:10.1111/j.1550-7408.2003.tb00648.x · Cited by 12 · see citing works
Self-citation
- Authors
- HUANG, L., MORRIS, A. M., & BEARD, C. B.
- Affiliations
- San Francisco General Hospital (US)
- University of Pittsburgh Medical Center (US)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- HUANG, LAURENCE
- Venue
- Journal of Eukaryotic Microbiology
- Publisher
- Wiley
- Published
- 2001-06
- Volume
- 48
- Issue
- s1
- Pages
- 180S-181S
- ISSN
- 1066-5234 (ISSN-L)
- 1550-7408
- OpenAlex
- W2004627956
- Cited by
- 10
- References
- 19
- Citations by year
- 2015: 1 · 2012: 1
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Eukaryotic Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Pneumocystis jirovecii pneumonia detection and treatment
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Parasitology › Parasitic Infections and Diagnostics
- Keywords
- Pneumocystis carinii, dihydropteroate synthase, sulfonamide resistance, sulfonamides, drug resistance mutations, standardized definitions, clinical evaluation
- MeSH terms
- Anti-Infective Agents, Dapsone, Dihydropteroate Synthase, Humans, Mutation, Pneumocystis, Pneumonia, Pneumocystis, Trimethoprim, Sulfamethoxazole Drug Combination, Treatment Outcome, Treatment Failure, Antibiotic Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
